Henning, Mattias A. S. http://orcid.org/0000-0003-1991-2248
Thorlacius, Linnea http://orcid.org/0000-0002-3734-9607
Ibler, Kristina S. http://orcid.org/0000-0002-5324-1591
Jemec, Gregor B. E. http://orcid.org/0000-0002-0712-2540
Funding for this research was provided by:
LEO Fondet (LF 18002)
Article History
Received: 1 December 2020
Accepted: 2 March 2021
First Online: 27 March 2021
Declarations
:
: Dr. Henning reports grants from the Leo Foundation, Denmark (number LF 18002) during the conduct of the study. Dr. Thorlacius reports personal fees from UCB, nonfinancial support from Abbvie, and nonfinancial support from Janssen, outside the submitted work. Dr. Ibler reports personal fees from LEO pharma, Astra Zeneca, and Sanofi. Dr. Jemec reports grants and personal fees from Abbvie, personal fees from Coloplast, personal fees from Chemocentryx, personal fees from LEO pharma, grants from LEO Foundation, grants from Afyx, personal fees from Incyte, grants and personal fees from InflaRx, grants from Janssen-Cilag, grants and personal fees from Novartis, grants and personal fees from UCB, grants from CSL Behring, grants from Regeneron, grants from Sanofi, personal fees from Kymera, and personal fees from VielaBio, outside the submitted work.
: Ethics approval is not applicable to this review article as it is based on already published data.
: The manuscript does not contain clinical studies or patient data.
: Not applicable.
: Not applicable.